Three questions that tell you what any peptide claim is actually worth.
Every claim you will meet about a peptide — in a forum, a product page, a video, or one of our guides — traces back to studies you are never going to read. That is fine. You do not need to read them. You need to know what kind of study is being waved at you, because that single fact does most of the work.
The three questions, in order of how much they tell you:
Most confident claims in this space fail the first question. The rest of this page is why that matters more than it sounds.
Not all evidence is the same kind of thing. Roughly, from least to most informative about what will happen in a person:
A claim is only as strong as the rung it stands on. "Shown to promote healing" means something very different resting on rung two than on rung four, and the phrasing is usually identical.
This is the number worth carrying around. A 2023 review in ATLA puts it plainly: the failure rate for translating drugs from animal testing to human treatments remains at over 92%, where it has been for several decades.
The reason matters as much as the number. The majority of those failures are unexpected toxicity — safety problems that showed up in human trials and were not apparent in the animal tests — or lack of efficacy. So the animal work does not merely fail to predict benefit; it routinely fails to predict harm.
One honest caveat, because this guide is about weighing evidence rather than winning an argument: that 92% figure is not the only way to measure translation. A separate 2023 analysis in ALTEX used different metrics — field-level success and the share of phase-2 trials with a positive outcome — and found considerably higher rates, around 62–72% depending on the field. The two are measuring different things, and which one applies depends on what you are asking. Both are in the references; read them rather than taking either number from us.
So when a compound has an impressive animal literature and no human data, the honest reading is not "very promising, just not formally approved yet." It is closer to: this is at the stage where nine out of ten things fail, and the most common way they fail is by hurting someone in a way the animal studies missed.
That is not an argument that any particular compound is dangerous. It is an argument about how much weight the phrase "studies show" can carry when all the studies are preclinical.
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeStudy counts are the most common way people talk themselves into confidence, because a count is quoted without the composition.
The pattern repeats across this whole category: a compound with a hundred-plus published papers, of which the overwhelming majority are cell culture and animal work, and a handful — sometimes two or three — involve humans at all. A 2025 systematic review of one of the most widely used peptides in sports medicine examined 36 studies and found 35 of them preclinical, with a single human clinical study among them.
So the useful move when you see a number is to ask what it is a number of. "Over 100 studies" and "over 100 human trials" differ by roughly everything, and only one of them is ever true.
A subtler problem: a literature can be large and still rest almost entirely on one research group.
When most of the work on a compound comes from a single lab, you are not looking at a hundred independent confirmations. You are looking at one team's programme, repeated. That is not misconduct — it is often just how a niche field develops — but it means the findings have not survived the thing that makes science reliable, which is someone unconnected trying and getting the same answer.
You can check this without expertise. Look at the author lists and affiliations on the citations. If the same names and the same institution appear on most of them, independent replication is thin, and that is worth knowing regardless of how many papers there are.
Dosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
Given a claim and a citation, here is the whole method:
Two free places to check anything yourself: PubMed for published literature, and ClinicalTrials.gov for registered human trials — including ones that were registered and then never reported results, which is its own useful signal.
Nothing above tells you where to buy, because sourcing is the part that varies most. Whoever you use, require the same three things:
The vendor we recommend — full panel published per batch. A reader discount applies automatically at checkout.
For research use only. Not for human consumption. 21+.
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreePreclinical means before humans — cells in a dish or animal models. Clinical means the study was conducted in people. Most peptide research is preclinical, and the distinction matters more than almost anything else about a study, because it determines whether the finding is about a person at all.
Often not. A 2023 ATLA review reports that the failure rate for translating drugs from animal testing to human treatments remains above 92%, roughly flat for decades, and that the majority of those failures are unexpected toxicity that animal tests did not reveal, or lack of efficacy. A separate 2023 analysis using different measures found higher success rates of around 62 to 72% by field, so the exact figure depends on what is being counted — but no measure supports treating animal results as though they carry over.
It depends entirely on what they are studies of. The usual pattern is that the overwhelming majority are cell culture and animal work with only a handful involving humans. One 2025 systematic review found 35 of 36 studies on a widely used peptide were preclinical, with a single human clinical study.
Read the abstract rather than the headline — it usually names the species in the first two sentences. Then look for the participant count and whether there was a control group. PubMed covers published literature and ClinicalTrials.gov covers registered human trials, including ones registered and never reported, which is informative in itself.
Because independent replication is what makes a finding reliable. A large literature dominated by a single research group is one team’s programme repeated rather than many groups converging on the same answer. Check the author lists and affiliations on the citations — repeated names mean replication is thinner than the paper count suggests.
Disclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor.
© 2026 StackTrax, LLC. All rights reserved.
Privacy · Terms · Do Not Sell or Share My Personal Information
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.